Abstract
Background In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now coined B.1.1.7. Based on the UK data and later additional data from other countries, a transmission advantage of around 40-80% was estimated for this variant [1, 2, 3].
Aim The goal of this study is to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time for data from Switzerland.
Methods We collected genomic surveillance data from 11.8% of all SARS-CoV-2 confirmed cases across Switzerland between 14.12.2020 and 11.03.2021. It allows us to determine the relative proportion of the B.1.1.7 variant on a daily basis and to quantify the transmission advantage of the B.1.1.7 variant on a national and a regional scale.
Results We propose a transmission advantage of 43-52% of B.1.1.7 compared to the other circulating variants. Further, we estimate a reproductive number for B.1.1.7 above 1 for Jan. 1, 2021 until now while the reproductive number for the other variants was below 1. In particular, for the time period up to Jan. 17 we obtain a reproductive number of 1.24 [1.07-1.41] and from Jan. 18 until March 1 we obtain 1.18 [1.06-1.30] based on the whole genome sequencing data. For March 10-16, we obtain 1.14 [1.00-1.26] based on all confirmed cases among which B.1.1.7 is dominant at this stage. Switzerland tightened measures on 18.01.2021 and released measures on 01.03.2021.
Conclusion In summary, the dynamics of increase in the frequency of B.1.1.7 is as expected based on the observations in the UK. B.1.1.7 increased in absolute numbers exponentially with the point estimate for the doubling time being around 2-3.5 weeks. Our plots are available online and are currently regularly updated with new data to closely monitor the spread of B.1.1.7.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
TS acknowledges funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30_196267 and 31CA30_196348). CA received funding from the European Union Horizon 2020 research and innovation programme - project EpiPose (No 101003688).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics commission (Ethikkommission Nordwest- und Zentralschweiz) confirmed that our study is exempt from ethical oversight as it only considers viral RNA but no human data. The final letter is attached.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author affiliation changed
Data Availability
All used data and code are publicly available.
https://github.com/cevo-public/Quantification-of-the-spread-of-a-SARS-CoV-2-variant
